Pluchart Hélène, Chanoine Sébastien, Moro-Sibilot Denis, Chouaid Christos, Frey Gil, Villa Julie, Degano Bruno, Giaj Levra Matteo, Bedouch Pierrick, Toffart Anne-Claire
Pôle Pharmacie, Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, France.
Université Grenoble Alpes, Grenoble, France.
Front Pharmacol. 2024 Feb 21;14:1016976. doi: 10.3389/fphar.2023.1016976. eCollection 2023.
Most patients with lung cancer are smokers and are of advanced age. They are therefore at high risk of having age- and lifestyle-related comorbidities. These comorbidities are subject to treatment or even polypharmacy. There is growing evidence of a link between lung cancer, comorbidities and medications. The relationships between these entities are complex. The presence of comorbidities and their treatments influence the time of cancer diagnosis, as well as the diagnostic and treatment strategy. On the other hand, cancer treatment may have an impact on the patient's comorbidities such as renal failure, pneumonitis or endocrinopathies. This review highlights how some comorbidities may have an impact on lung cancer presentation and may require treatment adjustments. Reciprocal influences between the treatment of comorbidities and anticancer therapy will also be discussed.
大多数肺癌患者为吸烟者且年龄较大。因此，他们患与年龄和生活方式相关的合并症的风险很高。这些合并症需要治疗，甚至可能需要联合用药。越来越多的证据表明肺癌、合并症和药物之间存在联系。这些实体之间的关系很复杂。合并症的存在及其治疗会影响癌症诊断的时间以及诊断和治疗策略。另一方面，癌症治疗可能会对患者的合并症产生影响，如肾衰竭、肺炎或内分泌病。本综述强调了一些合并症如何可能影响肺癌的表现，以及可能需要调整治疗。还将讨论合并症治疗与抗癌治疗之间的相互影响。
